Compare EPR Properties (EPR) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs Inovio Pharmaceuticals Inc — how do they compare? EPR Properties trades at $61.99 (market cap $4.60B), while Inovio Pharmaceuticals Inc trades at $1.13 (market cap $96.26M). The key difference: EPR Properties is far larger — about 47.8× Inovio Pharmaceuticals Inc's market cap, and EPR Properties pays a 6.19% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| EPR | INO | |
|---|---|---|
Market Cap | $4.60B | $96.26M |
Sector | Real Estate | Health |
52-Week High | $60.81 | $2.87 |
52-Week Low | $48.71 | $1.05 |
Enterprise Value | $7.66B | $67.27M |
Dividend Yield | 6.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
INO trades at $1.14, down 1.72% today, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 but has consistently beaten EPS estimates recently. Cash flow remains negative, though operating expenses are declining. A key FDA decision on INO-3107 is expected by October 30, 2026, representing a major catalyst.
The outlook hinges on regulatory approval for INO-3107. While analyst consensus is moderately bullish (53% buy ratings), significant financial losses and high valuation ratios pose substantial risks. The stock is a high-risk, event-driven investment dependent on successful drug commercialization to reverse its negative profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
